SutroVax raises $22 million in Series A

SutroVax raises $22 million in Series A Press release published by SutroVax, Vaccine Spin-off from Sutro Biopharma to Utilize Site-Specific Conjugation Technology Read more Vaccine Spin-off from Sutro Biopharma to Utilize Site-Specific Conjugation Technology South San...
Sutro Biopharma, Inc.
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.